FLT3 and acute myeloid leukemia: The prevalence of FLT3 mutations in AML has been reported to range from 12% to 30%.2,3,5,8,9,11,17,22,25,29,33 FLT3 inhibitors including sorafenib, midostaurin, and gilteritinib were received by patients in this study, and newer-generation FLT3 inhibitors quizartinib and crenolanib are under investigation.